In a report released today, Chris Muller from JMP Securities reiterated a Hold rating on Sachem Capital (SACH – Research Report). The ...
Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRaME-P1, a registration-enabling trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback